• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Management

Does Statin Use Confer a Reduced Risk for COVID-19 Mortality?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Bergqvist et al. (PLoS Medicine, 2021) assessed the relationship between statin use and COVID-19 mortality

METHODS:

  • Cohort study
    • Registries
    • Routinely collected data
  • Participants
    • All residents residing in Stockholm (March 1 2019 to February 29 2020)
    • ≥45 years
  • Exposure
    • Statin treatment | Initiated prior to the COVID-19 pandemic to avoid bias due to altered healthcare related to the pandemic
  • Study design
    • Hazard ratios (HRs) were calculated using multivariable Cox regression models
    • Subgroup analyses: Age groups | Sexes | Different statin indications | COVID-19 risk groups
    • Follow-up from March 2020 to November 2020
  • Primary outcome
    • COVID-19 specific mortality (Swedish Cause of Death Registry)

RESULTS:

  • 963,876 adults
    • 51.6% female
    • Statin users: 17.6%
  • Statin users were
    • Older
      • Users: 71.0 years
      • Non-users: 58.0 years
    • More likely to be male
      • Users: 53.3%
      • Non-users: 46.7%
    • More often diagnosed with comorbidities (e.g., ischemic heart disease)
    • More frequently on anticoagulant and antihypertensive treatments
    • Less likely to have a university-level education
      • Users: 34.5%
      • Non-users: 45.4%
    • More likely to have a low disposable income
      • Users: 20.6%
      • Non-users: 25.2%
    • Less likely to reside in crowded housing
      • Users: 6.1%
      • Non-users: 10.3%
  • COVID-19 specific mortality
    • Deaths during follow up: 2545 individuals
      • Deaths of statin users: 0.5%
      • Deaths of non-users: 0.2%
  • Statin treatment was associated with a lowered COVID-19 mortality
    • Adjusted HR 0.88 (95% CI, 0.79 to 0.97); P=0.01
  • This association did not vary appreciably across age groups, sexes, or COVID-19 risk groups

CONCLUSION:

  • There was a moderately lower risk of COVID-19 mortality among statin users
  • In keeping with previous studies | Current study has the benefit of including not just hospitalized patients, but the total population of Stockholm County
  • The authors state

In the absence of results from randomized clinical trials, our study can provide some guidance

Specifically, it gives further support for continuing statin treatment for conditions such as cardiovascular disease and hyperlipidemia, in line with current recommendations, during the COVID-19 pandemic

Learn More – Primary Sources:

HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

Is Statin Use Associated with Better COVID-19 Hospitalization Outcomes?
Are ACE Inhibitors and ARBs Associated with Increased COVID-19 Susceptibility?
RCT Results: Therapeutic or Prophylactic Anticoagulation for Hospitalized COVID-19 Patients?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site